| 题名 | A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer | | 作者 | Zhang Y1, Gao C, Qu W, Gao Y, Zhu S, Zhang S, He W, Yu Y. | | 杂志 | Cancer Invest. 2015 Jul;33(6):241-5. | | 链接 | http://xueshu.baidu.com/s?wd=paperuri%3A%28d46087620d9ca6b5aadb95f63c9470d3%29&filter=sc_long_sign&tn=SE_xueshusource_2kduw22v&sc_vurl=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F25951232&ie=utf-8&sc_us=1054513650024059969 |
本帖最后由 lo7ve77 于 2018-7-17 14:23 编辑
| 
发表于 2018-7-15 11:26:29
淘帖
收藏
顶
踩
发表于 2018-7-15 11:26:30
